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With the concluding words of
her plenary talk at the 2016
Society for Maternal–Fetal Medi-
cine Annual Meeting – ‘I wouldn’t
advise my daughter take vaginal
progesterone’ – had Jane Norman
and the OPPTIMUM team placed
a proverbial nail in the coffin of the
only class of medication routinely
used for the prevention of preterm
birth (PTB)? For practitioners in a
field with tragically few effective
interventions, it is imperative that
we cast a critical eye on even the
most robust randomised controlled
trial (RCT).
First, although OPPTIMUM studied
1197 women, the inclusion criteria
were remarkably broad. This is
curious, as the clinical efficacy of
progestogens differs not only by
formulation (e.g. natural vaginal
versus synthetic intramuscular), but
also by indication (e.g. prior PTB
or short cervix). The OPPTIMUM
study design almost immediately
forced us to think about subgroup
analyses. Though asymptomatic
cervical shortening remains the pri-
mary indication for vaginal proges-
terone (ACOG Practice
Bulletin 130, October 2012), in
OPPTIMUM the subgroup with a
cervical length of <25 mm was lim-
ited to only 256 women. In com-
parison, the American Congress of
Obstetricians and Gynecologists
(ACOG) based its recommenda-
tions on two RCTs of women with
short cervix length: both studies
randomised >410 women (Hassan
et al. Ultrasound Obstet Gynecol
2011;38:18–31; Fonseca et al.
N Engl J Med 2007;357:462–9).
Second, women were randomised
at 22–24 weeks of gestation, so
women delivering at 18–22 weeks
of gestation as a result of PTB (ar-
guably, those at highest risk) would
not have been eligible for randomi-
sation. Still others identified to be
at highest risk <22 weeks of gesta-
tion – particularly those with a very
short cervix – may have pursued
active treatment in lieu of waiting
several weeks to be randomised.
Furthermore, given that proges-
terone is hypothesized to work
through anti-inflammatory mecha-
nisms, do irreversible (and poten-
tially modifiable) changes occur
<22 weeks of gestation among
women destined to deliver pre-
term? Studies of intramuscular pro-
gesterone demonstrate increased
efficacy with earlier initiation of
treatment (Markham et al.
Obstet Gynecol 2014;123:34–9). As
several OPPTIMUM point esti-
mates favour progesterone, we
can’t help but wonder if the right
treatment was administered but
just started too late to be effica-
cious.
Finally, the trial has been broadly
described as a negative one.
Although no significant reduction in
the composite primary outcomes
was identified, vaginal progesterone
was associated with a significant 
reduction in neonatal death (odds 
ratio, OR 0.17; 95% confidence 
interval, 95% CI 0.06–0.49) and 
neonatal brain injury (OR 0.50; 
95% CI 0.31–0.84). Perhaps on this 
point alone our opinions and the 
opinions of our patients diverge 
regarding the significance of the 
results? Or, as the Patient-Cen-
tered Outcomes Research Institute 
(PCORI) literature challenges us, 
who is best positioned to select 
the outcomes around which our 
studies should be powered?
Progestogens are estimated to pre-
vent nearly 20 000 PTBs in the US 
annually (Schoen et al. AJOG 
2015;213(2):175–180). Despite 
this, many others cannot be pre-
vented. This work is a tremendous 
contribution, yet does not warrant 
practice change. As perinatologists 
we echo the authors’ call for a ‘re-
doubling of efforts to find alterna-
tive strategies to prevent preterm 
birth in women at risk’. Until that 
time, however, we will continue to 
prescribe the only class of medica-
tion with proven efficacy and safety 
for PTB prevention; progestogens. 
Our patients, and our daughters, 
deserve no less.
Disclosure of interests
None declared. Completed disclo-
sure of interests form available to 
view online as supporting informa-
tion. 
